Zobrazeno 1 - 10
of 73
pro vyhledávání: '"S Carparelli"'
Autor:
F Bossa, S Carparelli, M Guerra, F Cocomazzi, G Martino, M Annese, M Nardella, N Bellucci, R Gagliardi, F Terracciano, L Pacilli, F Perri
Publikováno v:
Journal of Crohn's and Colitis. 17:i606-i607
Background Crohn’s disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Telemedicine (TM) is particularly useful in patients with chronic diseases who need frequent monitoring to achieve therapeutic outcomes and i
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F. Terracciano, A. Marra, F. Bossa, V. Nassisi, S. Carparelli, M.R. Valvano, F. Cocomazzi, F. Perri
Publikováno v:
Digestive and Liver Disease. 55:S179
Autor:
Mariabeatrice Principi, Francesco Abbruzzi, Alfredo Di Leo, S. Carparelli, Enzo Ierardi, Ilaria Loconte
Publikováno v:
Current Drug Safety. 15:65-68
Background: Olmesartan, an antihypertensive drug, may be associated with a severe “sprue-like enteropathy”. Objectives: To report a case of Olmesartan enteropathy demonstrated by video capsule endoscopy distally from the second duodenum along wit
Autor:
S. Onali, D. Pugliese, F.A. Caprioli, A. Orlando, L. Biancone, O.M. Nardone, N. Imperatore, G. Fiorino, M. Cappello, A. Viola, M.B. Principi, C. Bezzio, A. Aratari, S. Carparelli, F. Mancuso, L. Grossi, G. Bodini, D. Ribaldone, G. Mocci, A. Favale, M. Grova, L. Scucchi, S. Segato, W. Fries, F. Castiglione, A. Armuzzi, M.C. Fantini
Publikováno v:
Digestive and Liver Disease. 54:S140-S141
Autor:
S Onali, D Pugliese, F A Caprioli, A Orlando, L Biancone, O M Nardone, N Imperatore, G Fiorino, M Cappello, A Viola, M B Principi, C Bezzio, A Aratari, S Carparelli, S Mazzuoli, F Manguso, L Grossi, G Bodini, D Ribaldone, G Mocci, L Minerba, A Favale, M Grova, L Scucchi, S Segato, W Fries, F Castiglione, A Armuzzi, M C Fantini
Publikováno v:
Journal of Crohn's and Colitis. 16:i542-i543
Background The use of ustekinumab (UST) and vedolizumab (VDZ) as second line therapy in Crohn’s disease (CD) patients failing tumour necrosis factor alpha inhibitors is still debated. The aim of the study was to compare in a large multicentre obser
Autor:
C Bezzio, A D Guarino, G Fiorino, A Armuzzi, D G Ribaldone, F Furfaro, D Pugliese, M Vernero, A Variola, V Gerardi, L Scucchi, C Viganò, F A Caprioli, J Roselli, F Coppini, S Ardizzone, S Onali, F Zingone, M Daperno, C Cortellezzi, S Carparelli, A Soriano, G Manes, S Saibeni
Publikováno v:
Journal of Crohn's and Colitis. 16:i228-i229
Background In the last year, the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has spread rapidly around the world. The interactions between SARS-CoV-2 and inflammatory bowel disease (IBD) are so far not fully understood. In p
Autor:
S. Carparelli, Rosa Nitti, Alfredo Di Leo, Annagrazia Cecere, Marco Matteo Ciccone, Fabio Manca, Pietro Scicchitano, Roberta Ruggieri, Maria Consiglia Bellino, Mariabeatrice Principi
Publikováno v:
Minerva medica. 113(2)
Background Inflammatory bowel diseases (IBD) may be complicated by extraintestinal manifestations (EIM). Both conditions may be implicated in the overall increase of cardiovascular (CV) risk profile of the patients. The study aimed to assess CV risk
Autor:
S, Carparelli, M R, Pastore, M R, Valvano, A, Marseglia, A, Latiano, O, Palmieri, M, Guerra, G, Martino, F, Perri, F, Bossa
Publikováno v:
European review for medical and pharmacological sciences. 25(6)
From September 2020, a second wave of COVID-19 pandemic started. We aimed at exploring the impact of SARS-CoV-2 infection in IBD patients during the two waves.All IBD patients with a confirmed diagnosis of SARS-CoV-2 infection were enrolled. They wer
Autor:
F. Terracciano, A. Marra, F. Bossa, A. Dirodi, M.A. Ippolito, S. Carparelli, M.R. Pastore, M.R. Valvano, A. Marseglia, M. D’Altilia, D. Ferrara, C. Bucci, F. Esposito, F. Perri
Publikováno v:
Digestive and Liver Disease. 54:S98